Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Rinat Cohen-Moreno, Miriam Schiff, Shabtay Levitt, Rachel Bar-Hamburger, Shiela Strauss & Yehuda Neumark. (2010) Knowledge About Hepatitis-C Among Methadone Maintenance Treatment Patients in Israel. Substance Use & Misuse 45:1-2, pages 58-76.
Read now
Read now
Angela L Stotts, Carrie L Dodrill & Thomas R Kosten. (2009) Opioid dependence treatment: options in pharmacotherapy. Expert Opinion on Pharmacotherapy 10:11, pages 1727-1740.
Read now
Read now
CorrineE. Munoz-Plaza, ShielaM. Strauss, JanettaM. Astone-Twerwll, DonC. Des Jarlais & Holly Hagan. (2006) Staff Perspectives on Facilitating the Implementation of Hepatitis C Services at Drug Treatment Programs. Journal of Psychoactive Drugs 38:3, pages 233-241.
Read now
Read now
Janetta M. Astone, Shiela M. Strauss, Holly Hagan & Don C. Des Jarlais. (2004) Outpatient Drug Treatment Program Directors' Hepatitis C‐Related Beliefs and Their Relationship to the Provision of HCV Services. The American Journal of Drug and Alcohol Abuse 30:4, pages 783-797.
Read now
Read now
Articles from other publishers (32)
Karli R Hochstatter, David H Gustafson Sr, Gina Landucci, Klaren Pe-Romashko, Olivia Cody, Adam Maus, Dhavan V Shah & Ryan P Westergaard. (2021) Effect of an mHealth Intervention on Hepatitis C Testing Uptake Among People With Opioid Use Disorder: Randomized Controlled Trial. JMIR mHealth and uHealth 9:2, pages e23080.
Crossref
Crossref
Yi Zheng, Samuel Obeng, Bethany A. Reinecke, Chongguang Chen, Palak S. Phansalkar, David M. Walentiny, Phillip M. Gerk, Lee-Yuan Liu-Chen, Dana E. Selley, Patrick M. Beardsley & Yan Zhang. (2019) Pharmacological characterization of 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3′-fluoro-4′-pyridyl)acetamido]morphinan (NFP) as a dual selective MOR/KOR ligand with potential applications in treating opioid use disorder. European Journal of Pharmacology 865, pages 172812.
Crossref
Crossref
Karli R Hochstatter, David H Gustafson Sr, Gina Landucci, Klaren Pe-Romashko, Adam Maus, Dhavan V Shah, Quinton A Taylor, Emma K Gill, Rebecca Miller, Sarah Krechel & Ryan P Westergaard. (2019) A Mobile Health Intervention to Improve Hepatitis C Outcomes Among People With Opioid Use Disorder: Protocol for a Randomized Controlled Trial. JMIR Research Protocols 8:8, pages e12620.
Crossref
Crossref
Yi Zheng, Samuel Obeng, Huiqun Wang, Abdulmajeed M. Jali, Bharath Peddibhotla, Dwight A. Williams, Chuanchun Zou, David L. Stevens, William L. Dewey, Hamid I. Akbarali, Dana E. Selley & Yan Zhang. (2019) Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4′-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands. Journal of Medicinal Chemistry 62:2, pages 561-574.
Crossref
Crossref
Monica L. Kasting, Anna R. Giuliano, Richard R. Reich, Richard G. Roetzheim, David R. Nelson, Elizabeth Shenkman & Susan T. Vadaparampil. (2018) Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013–2015. Cancer Epidemiology, Biomarkers & Prevention 27:4, pages 503-513.
Crossref
Crossref
Trena I. Mukherjee, Veena Pillai, Siti Hafizah Ali, Frederick L. Altice, Adeeba Kamarulzaman & Jeffrey A. Wickersham. (2017) Evaluation of a hepatitis C education intervention with clients enrolled in methadone maintenance and needle/syringe programs in Malaysia. International Journal of Drug Policy 47, pages 144-152.
Crossref
Crossref
Hildi J. Hagedorn, Nancy Rettmann, Eric Dieperink, Astrid Knott & Bruce E. Landon. (2015) A Training Model for Implementing Hepatitis Prevention Services in Substance Use Disorder Clinics: A Qualitative Evaluation. Journal of General Internal Medicine 30:8, pages 1215-1221.
Crossref
Crossref
Yvette Calderon, Ethan Cowan, Christopher Schramm, Sam Stern, Christopher Brusalis, Mark Iscoe, Sara Rahman, Rajesh Verma & Jason Leider. (2014) HCV and HBV testing acceptability and knowledge among urban emergency department patients and pharmacy clients. Preventive Medicine 61, pages 29-33.
Crossref
Crossref
Jemima A. Frimpong. (2013) Missed Opportunities for Hepatitis C Testing in Opioid Treatment Programs. American Journal of Public Health 103:6, pages 1028-1030.
Crossref
Crossref
Christopher E. McGowan, Ali Monis, Bruce R. Bacon, Josep Mallolas, Fernando L. Goncales, Ioannis Goulis, Fred Poordad, Nezam Afdhal, Stefan Zeuzem, Teerha Piratvisuth, Patrick Marcellin & Michael W. Fried. (2013) A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care. Hepatology 57:4, pages 1325-1332.
Crossref
Crossref
Christopher E. McGowan & Michael W. Fried. (2012) Barriers to hepatitis C treatment. Liver International 32, pages 151-156.
Crossref
Crossref
Christian D Helfrich, Dean Blevins, Jeffrey L Smith, P Adam Kelly, Timothy P Hogan, Hildi Hagedorn, Patricia M Dubbert & Anne E Sales. (2011) Predicting implementation from organizational readiness for change: a study protocol. Implementation Science 6:1.
Crossref
Crossref
Ann DrobnikCaroline JuddDavid BanachJoseph EggerKevin KontyEric Rude. (2011) Public Health Implications of Rapid Hepatitis C Screening With an Oral Swab for Community-Based Organizations Serving High-Risk Populations. American Journal of Public Health 101:11, pages 2151-2155.
Crossref
Crossref
Christopher Mark Milroy & Jacqueline Louise Parai. (2011) The histopathology of drugs of abuse. Histopathology 59:4, pages 579-593.
Crossref
Crossref
Adeline Nyamathi, Darlene Tyler, Karabi Sinha, Mary Marfisee, Allan Cohen & Barbara Greengold. (2010) Predictors of Hepatitis Knowledge Improvement Among Methadone Maintained Clients Enrolled in a Hepatitis Intervention Program. Journal of Community Health 35:4, pages 423-432.
Crossref
Crossref
Corrine Munoz-Plaza, Shiela M. Strauss, Nelson Tiburcio, Janetta M. Astone-Twerell, Don C. Des Jarlais, Marya Gwadz, Holly Hagan, Andrew Osborne & Andrew Rosenblum. (2010) Research Note: Perspectives on the Hierarchy of HIV and Hepatitis C Disease: Consequences for Drug Treatment Program Patients. Journal of Drug Issues 40:2, pages 517-535.
Crossref
Crossref
Kevin A. Sevarino & Thomas R. Kosten. 2009. Opiate Receptors and Antagonists. Opiate Receptors and Antagonists
227
245
.
Shiela M. Strauss, Corrine Munoz-Plaza, Nelson Jose Tiburcio, Janetta Astone-Twerell, Don C. Des Jarlais, Marya Gwadz, Holly Hagan, Andrew Osborne & Andrew Rosenblum. (2008) Barriers and Facilitators to Undergoing Hepatitis C Virus (HCV) Testing through Drug Treatment Programs. Journal of Drug Issues 38:4, pages 1161-1185.
Crossref
Crossref
Corrine E. Munoz-Plaza, Shiela Strauss, Janetta Astone-Twerell, Don Des Jarlais, Marya Gwadz, Holly Hagan, Andrew Osborne & Andrew Rosenblum. (2008) Exploring drug users’ attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S.. International Journal of Drug Policy 19:1, pages 71-78.
Crossref
Crossref
Shiela M Strauss, Janetta Astone-Twerell, Corrine E Munoz-Plaza, Don C Des Jarlais, Marya Gwadz, Holly Hagan, Andrew Osborne & Andrew Rosenblum. (2007) Drug treatment program patients' hepatitis C virus (HCV) education needs and their use of available HCV education services. BMC Health Services Research 7:1.
Crossref
Crossref
Hildi Hagedorn, Eric Dieperink, Debra Dingmann, Janet Durfee, Samuel B. Ho, Carl Isenhart, Nancy Rettmann & Mark Willenbring. (2007) Integrating hepatitis prevention services into a substance use disorder clinic. Journal of Substance Abuse Treatment 32:4, pages 391-398.
Crossref
Crossref
SHIELA M. STRAUSS, JANETTA M. ASTONE-TWERELL, CORRINE MUNOZ-PLAZA, DON C. DES JARLAIS, MARYA GWADZ, HOLLY HAGAN, ANDREW OSBORNE & ANDREW ROSENBLUM. (2006) HEPATITIS C KNOWLEDGE AMONG STAFF IN U.S. DRUG TREATMENT PROGRAMS. Journal of Drug Education 36:2, pages 141-168.
Crossref
Crossref
Corrine E. Munoz-Plaza, Shiela M. Strauss, Janetta M. Astone, Don C. Des Jarlais & Holly Hagan. (2018) HCV (Hepatitis C Virus) Pre-Test and Post-Test Counseling Services at Drug Treatment Programs: Missed Opportunities for Primary Prevention. Contemporary Drug Problems 32:4, pages 655-675.
Crossref
Crossref
Mark Evans, Patricia S Hokanson, Jay Augsburger, Shelly L Sayre, Angela L Stotts & Joy M Schmitz. (2005) Increasing Knowledge of HIV and Hepatitis C During Substance Abuse Treatment. Addictive Disorders & Their Treatment 4:2, pages 71-76.
Crossref
Crossref
Alexander Y. Walley, Mary C. White, Margot B. Kushel, Yong S. Song & Jacqueline P. Tulsky. (2005) Knowledge of and interest in hepatitis C treatment at a methadone clinic. Journal of Substance Abuse Treatment 28:2, pages 181-187.
Crossref
Crossref
Corrine E. Munoz-Plaza, Shiela M. Strauss, Janetta M. Astone, Don C. Des Jarlais & Holly Hagan. (2016) Drug Treatment Programs as Sites of Opportunity for the Delivery of Hepatitis C Prevention Education: Client and Staff Perspectives. Journal of Drug Issues 34:4, pages 861-878.
Crossref
Crossref
Thomas F. Kresina, Jacques Normand, Jag Khalsa, Jennifer Mitty, Timothy Flanigan & Henry Francis. (2004) Addressing the Need for Treatment Paradigms for Drug-Abusing Patients with Multiple Morbidities. Clinical Infectious Diseases 38:Supplement_5, pages S398-S401.
Crossref
Crossref
Mark Evans, Angela L. Stotts, Susan Graham, Joy Schmitz & John Grabowski. (2004) Hepatitis C Knowledge Assessment and Counseling Within the Context of Substance Abuse Treatment. Addictive Disorders & Their Treatment 3:1, pages 18-26.
Crossref
Crossref
Shiela M Strauss, Janetta M Astone, Don Des Jarlais & Holly Hagan. (2004) A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States. Drug and Alcohol Dependence 73:3, pages 227-236.
Crossref
Crossref
Shiela M. Strauss, Janetta Astone, Zdravko P. Vassilev, Don C. Des Jarlais & Holly Hagan. (2003) Gaps in the drug-free and methadone treatment program response to Hepatitis C. Journal of Substance Abuse Treatment 24:4, pages 291-297.
Crossref
Crossref
Janetta Astone, Shiela M. Strauss, Zdravko P. Vassilev & Don C. Des Jarlais. (2003) Provision of Hepatitis C Education in a Nationwide Sample of Drug Treatment Programs. Journal of Drug Education 33:1, pages 107-117.
Crossref
Crossref
Shiela M. Strauss, Gregory P. Falkin, Zdravko Vassilev, Don C. Des Jarlais & Janetta Astone. (2002) A nationwide survey of hepatitis C services provided by drug treatment programs. Journal of Substance Abuse Treatment 22:2, pages 55-62.
Crossref
Crossref